Drugs Made In America Acquisition Corp.Securities Subscription Agreement • August 1st, 2024 • Drugs Made in America Acquisition Corp. • New York
This agreement (the “Agreement”) is entered into on June 14, 2024 by and between Drugs Made In America Acquisition LLC, a Delaware limited liability company (the “Subscriber” or “you”), and Drugs Made In America Acquisition Corp., a Cayman Islands exempted company (the “Company,” “we” or “us”). Pursuant to the terms hereof, the Company hereby accepts the offer the Subscriber has made to subscribe for and purchase 22,361,111 ordinary shares, $0.0001 par value per share of the Company (the “Shares”), up to 2,916,667 of which are subject to surrender and cancellation by you if the underwriters of the initial public offering (“IPO”) of units (“Units”) of the Company, do not fully exercise their over-allotment option (the “Over-allotment Option”). The Company and the Subscriber’s agreements regarding such Shares are as follows:
